Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that are at the forefront of drug discovery and development in oncology and immuno-oncology.
Providing a range of integrated solutions, including preclinical research services, translational platforms, and clinical trial support. Its offer includes the world's largest commercially available patient-derived xenograft (PDX) collection and more than 600 tumor organoid models utilizing Hubrecht Organoid Technology, covering 22 cancer indications.
Crown Bioscience's expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in vitro, ex vivo, and in silico methods, along with advanced laboratory services that span the entire drug development timeline. Additionally, it maintains an extensive biobank of liquid and human biospecimens, complete with clinical histories.
Crown Bioscience Organoids for Oncology Drug Development
Models of Drug Resistance
CrownCast: Exploring Artificial Intelligence in Drug Discovery
CrownCast: Navigating Challenges: Immune Cells vs Cancer Cells
CrownCast: Beyond the Lab: The Evolving Role of CROs
CrownCast: The Competitive Edge: How CROs Stay Ahead in Drug Discovery
Deep Learning Models in Preclinical Histopathology Image Analysis
SynAI: An AI-driven Cancer Drugs Synergism Prediction Platform
Effective Preclinical Solutions to Tackle Oncology Drug Resistance
A Novel Approach to Overcoming Limitations of T Cell Immunotherapies
Assay ready Organoid Drug Screening With Robust, Reproducible, and Clinically relevant Output
Large-Panel Organoid Screening: Bridging Reproducibility & Clinical Relevance in Oncology
RNA Degradation and Its Influence on Transcriptomic Profiling: A Case Study with Preclinical Samples
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
Targeting T Cells Within the Cancer Immunity Cycle
Analyzing the Suppressive TME in In Vitro Based Assays
What's Next in Preclinical Cancer Immunotherapy Research
Patient derived Systems for Immuno Oncology
Strategies for Patient derived Xenografts in Humanized Models
A Unique 3D High Content Imaging based Screening Assay to Evaluate Drug Responses in Patient Tumours
Organoid Co culture Platform for Immunotherapy Studies
Xenografts and Homografts—All Models Are Not Equal
Humanized Mouse Models for IO Drug Discovery
Predicting Clinical Response with Mouse Clinical Trials
Adding Value to Drug Development Through In Vivo Model Imaging
Accelerate IO Drug Development with a Fast, Cost Effective, and Powerful Screening Tool
Establishment of Next Generation Pretreated PDX Models A Tool for Precision Medicine
Integrated Preclinical Solutions to Guide Clinical Development of Bispecific Antibodies
Navigating Cancer Model Databases for Optimized Model Selection
Advancing Proteomics Profiling in Tumor Xenograft Models